Refractory Solid Tumor Clinical Trial
Official title:
Phase II Study With Oxaliplatin In Children With Relapsed/Refractory Solid Tumors
The purpose of this study is to determine the pediatric neoplastic response to chemotherapy proposed and evaluate sensitivity to oxaliplatin through immunohistochemistry ERCC-1 expression analysis.
n/a
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03690869 -
REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04238819 -
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT05468359 -
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
|
Phase 1/Phase 2 | |
Withdrawn |
NCT03443622 -
Phase I Study of SC-43 Oral Solution in Subjects With Refractory Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06375564 -
Clinical Evaluation of 177Lu-AB-3PRGD2 in Various Solid Tumors With Integrin αvβ3 Positive Expression
|
Phase 1 | |
Terminated |
NCT02164097 -
ODSH + ICE Chemotherapy in Pediatric Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05963386 -
Clinical Evaluation of 177Lu-DOTA-EB-FAPI in Patients With Various Solid Tumors
|
Phase 1 | |
Completed |
NCT00110357 -
Study of Erbitux™ (Cetuximab) in Pediatric Patients With Refractory Solid Tumors
|
Phase 1 |